In patients with ocular melanoma treated with prophylactic bevacizumab after plaque radiotherapy there was significant preservation in visual acuity compared with a control group, according to study results presented by Carol L. Shields, MD, said at the Wills Eye Conference.

The researchers aimed to determine if continuous bevacizumab treatment could change visual outcomes for plaque radiotherapy recipients in 3 years.

Previous studies showed that one injection of an anti-VEGF agent did not change visual outcomes for plaque radiotherapy recipients; however, Shields and her…

View Conference Coverage

Take a look at some of our conference coverage, visit our roundup section.